Aquestive Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.56
- Today's High:
- $1.7
- Open Price:
- $1.57
- 52W Low:
- $0.618
- 52W High:
- $2.95
- Prev. Close:
- $1.57
- Volume:
- 245893
Company Statistics
- Market Cap.:
- $46.03 million
- Book Value:
- -2.002
- Revenue TTM:
- $48.08 million
- Operating Margin TTM:
- -89.49%
- Gross Profit TTM:
- $35.84 million
- Profit Margin:
- -147.69%
- Return on Assets TTM:
- -45.91%
- Return on Equity TTM:
- 0%
Company Profile
Aquestive Therapeutics Inc had its IPO on 2018-07-25 under the ticker symbol AQST.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Aquestive Therapeutics Inc has a staff strength of 157 employees.
Stock update
Shares of Aquestive Therapeutics Inc opened at $1.57 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.56 - $1.7, and closed at $1.66.
This is a +5.73% increase from the previous day's closing price.
A total volume of 245,893 shares were traded at the close of the day’s session.
In the last one week, shares of Aquestive Therapeutics Inc have slipped by -0.6%.
Aquestive Therapeutics Inc's Key Ratios
Aquestive Therapeutics Inc has a market cap of $46.03 million, indicating a price to book ratio of 0 and a price to sales ratio of 1.0139.
In the last 12-months Aquestive Therapeutics Inc’s revenue was $48.08 million with a gross profit of $35.84 million and an EBITDA of $-40114000. The EBITDA ratio measures Aquestive Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aquestive Therapeutics Inc’s operating margin was -89.49% while its return on assets stood at -45.91% with a return of equity of 0%.
In Q3, Aquestive Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 13.7%.
Aquestive Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aquestive Therapeutics Inc’s profitability.
Aquestive Therapeutics Inc stock is trading at a EV to sales ratio of 1.7944 and a EV to EBITDA ratio of -1.5989. Its price to sales ratio in the trailing 12-months stood at 1.0139.
Aquestive Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $51.85 million
- Total Liabilities
- $36.56 million
- Operating Cash Flow
- $-1717000.00
- Capital Expenditure
- $1.72 million
- Dividend Payout Ratio
- 0%
Aquestive Therapeutics Inc ended 2024 with $51.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $51.85 million while shareholder equity stood at $-107819000.00.
Aquestive Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $36.56 million in other current liabilities, 54000.00 in common stock, $-298855000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.65 million and cash and short-term investments were $18.65 million. The company’s total short-term debt was $15,071,000 while long-term debt stood at $38.68 million.
Aquestive Therapeutics Inc’s total current assets stands at $38.09 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $10.74 million compared to accounts payable of $11.07 million and inventory worth $6.73 million.
In 2024, Aquestive Therapeutics Inc's operating cash flow was $-1717000.00 while its capital expenditure stood at $1.72 million.
Comparatively, Aquestive Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.66
- 52-Week High
- $2.95
- 52-Week Low
- $0.618
- Analyst Target Price
- $5.36
Aquestive Therapeutics Inc stock is currently trading at $1.66 per share. It touched a 52-week high of $2.95 and a 52-week low of $2.95. Analysts tracking the stock have a 12-month average target price of $5.36.
Its 50-day moving average was $1.76 and 200-day moving average was $1.39 The short ratio stood at 7.41 indicating a short percent outstanding of 0%.
Around 242.9% of the company’s stock are held by insiders while 2769% are held by institutions.
Frequently Asked Questions About Aquestive Therapeutics Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company’s proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.